Clinical trials: First Pregnancy
Ovarian Cancer
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Study Design: This ia a Phase II study. Subjects: Patients with chemotherapy naive epithelial ovarian cancer; or fallopian, primary peritoneal and papillary serous mullerian tumors will be recruited.
- Trial name
- NCT00129727
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Malignant Pleural Mesothelioma
Autologous Dendritic Cell Vaccination in Mesothelioma
In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural…
- Trial name
- MESODEC (NCT02649829)
- Testing
- dendritic cell vaccination plus chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 28 people
- Sponsor
- University Hospital, Antwerp
Bladder Cancer
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with…
- Trial name
- NCT07232602
- Testing
- MK-3120, EV, Pembrolizumab
- Where
- 17 sites in United States, Chile and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Melanoma
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may…
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05354102
- Testing
- BMC128, Nivolumab
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Biomica Ltd.
Breast Cancer, Ovarian Cancer
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
- Trial name
- NCT07524322
- Testing
- RGT-490
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Regor Pharmaceuticals Inc.
Ovarian Neoplasms, Prostatic Neoplasms
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug.
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
- Trial name
- NCT06751329
- Testing
- DM002
- Where
- 7 sites in United States, Australia
- Volunteers
- 280 people
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer Stage I
Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins
The goal of this [ Can second resection for pT1 bladder carcinoma be safely avoided after initial En-Bloc Resection with negative vertical and horizontal safety margins ? is to assess the impact of avoiding re TUR on Recurrence…
- Trial name
- NCT05969964
- Testing
- Avoid second resection after initial complete resection
- Where
- Egypt
- Volunteers
- 370 people
- Sponsor
- Mansoura University
Metastatic Renal Cell Carcinoma
Cost Effectiveness Of Sunitinib In Central America And Caribbean
Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America and Caribbean countries
- Trial name
- NCT01033981
- Testing
- Sunitinib
- Where
- Panama
- Volunteers
- 4 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
MEtatastic Renal Carcinoma LINes
The hypothesis of this study are as follows: Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
- Trial name
- MERLIN (NCT03928964)
- Where
- 8 sites in France
- Volunteers
- 440 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Fetal Conditions
Early Pregnancy Ultrasound Parameters Including Corpus Luteum Doppler in Prediction of First Trimester Pregnancy Outcome in Spontaneous Pregnancies.
The synthesis of progesterone by corpus luteum is extremely important for the maintenance of normal pregnancy in the first seven weeks.
- Trial name
- NCT07204028
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cairo University
Preeclampsia (PE)
Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)
The purpose of this study is to determine whether first-trimester screening for preeclampsia based on the FMF algorithm (a combination of maternal clinical, sonographic and biochemical parameters), improves maternal or perinatal…
- Trial name
- RANSPRE (NCT05521776)
- Testing
- First-trimester preeclampsia screening (FMF triple test)
- Where
- 22 sites in France
- Volunteers
- 14,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Incomplete Abortion, Intrauterine Contraception
Ideal Timing of Intrauterine Contraception Insertion After Medical Management of First Trimester Incomplete Abortion
Background: Unintended pregnancies continue to cause a public health threat in Low and Middle Income countries yet with restrictive abortion laws.
- Conditions
- Incomplete Abortion, Intrauterine Contraception, Misoprostol
- Trial name
- PAIC (NCT05343546)
- Testing
- Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion
- Where
- Uganda
- Volunteers
- 2,076 people
- Sponsor
- Makerere University
Primary Cesarean Section
Primary Cesarean Section in Primigravida and Muligravida in Sohag and Al Balyana Cities
cesarean section and vaginal delivery are two methods of delivery, cesarean section somtimes indicated for obstetrical reason but primary cesarean section especially in primigravida might have a preference of the mode of delivery
- Trial name
- NCT06083727
- Testing
- rate of cesarean section
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Retained Product of Conception After First Trimester Medical Abortion
Success Rates of Expectant vs. Medical Management for Retained Products After First-Trimester Abortion: Randomized Controlled Trial
This prospective randomized controlled trial evaluates the success of medical versus expectant management for retained products of conception (RPOC) following medical abortion with mifepristone and misoprostol for delayed…
- Trial name
- NCT07534982
- Testing
- medical management with misoprostol
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Yael Yagur
Clear-cell Renal Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma An open-label, exploratory, single-arm, multicenter trial.
- Trial name
- NEORAD (NCT01715935)
- Testing
- Everolimus
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Cervical Disease
Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies
The purpose of this study is to evaluate whether fluorescence and reflectance spectroscopy can improve the ability to detect the presence of premalignant lesions on the cervix.
- Trial name
- Spectral (NCT02217215)
- Testing
- CNDS Advanced Cervical Scan
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Guided Therapeutics
Cervical Cancer
First-void Urine Samples for the Follow-up of Women Treated for High-grade Cervical Intraepithelial Neoplasia (CIN)
The aim of this study is to analyse biomarkers in first-void urine for improved follow-up of women treated for high grade cervical intraepithelial neoplasia (CIN).
- Trial name
- NCT03542513
- Testing
- Colli-Pee, Qvintip
- Where
- Belgium
- Volunteers
- 65 people
- Sponsor
- Universiteit Antwerpen
Preterm, Breastfeeding
Breastfeeding and Bottle Feeding: Impact on Preterm Infants' Physiology and Feeding Performance
The goal of this clinical trial is to evaluate the effect of breastfeeding on the infant's test weight and physiological characteristics (oxygen saturation and heart rate) in preterm infants in the Neonatal Intensive Care Unit…
- Conditions
- Preterm, Breastfeeding, Bottlefeeding, Premature
- Trial name
- NCT05651035
- Testing
- oral feeding
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Ovarian Cancer
MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer
The purpose of this study is to evaluate the toxicity and activity of weekly administration of carboplatin and paclitaxel as first-line chemotherapy for elderly patients with ovarian cancer stage IC-IV.
- Trial name
- MITO-5 (NCT00401674)
- Testing
- carboplatin, paclitaxel
- Where
- 10 sites in Italy
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute, Naples
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.